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ABSTRACT
Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and
mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and
prostate cancers, confer sensitivity to poly-(ADP-ribose) polymerase inhibitors (PARPi). Our work, and
that of others, shows that PARPi selectively trigger tumor cell-autonomous immune phenotypes in
ERCC1- or BRCA-defective contexts. This suggests that PARPi, used in appropriately selected populations,
might mediate their therapeutic effects by potentiating anti-tumor immunity.
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DNA repair defects are a common hallmark of cancer that
likely contributes to tumorigenesis by promoting genomic
instability. This hallmark of cancer has been exploited ther-
apeutically for over 50 years with the use of classical che-
motherapies, which elicit cytotoxicity in tumor cells that are
unable to effectively repair DNA damage. More recently, the
identification of the synthetic lethal interaction between DNA
damage induced by poly-(ADP-ribose) polymerase inhibitors
(PARPi) and defects in the DNA repair tumor suppressor
genes BRCA1 and BRCA2 (known as breast cancer type 1/2
susceptibility genes), has led to a more targeted approach to
therapeutically exploiting specific DNA repair defects in bio-
marker-defined subsets of breast and ovarian cancers.1 For
example, the PARPi olaparib, rucaparib, and niraparib have
all been approved for the treatment of BRCA-gene mutant
advanced ovarian cancer, and olaparib and talazoparib have
been approved for the treatment of BRCA-gene mutant breast
cancer. Pre-clinical work has also demonstrated that defects in
other tumor suppressors that control DNA repair processes,
such as excision repair cross-complementation group 1
(ERCC1) defects in models of non-small cell lung cancer
(NSCLC), cause PARPi sensitivity.2 This has led to phase 2
clinical trials (e.g., NCT02679963) assessing the efficacy of
PARPi in this setting.
Alongside this progress, immune-based therapies – notably
antibodies targeting the programmed cell death-1/pro-
grammed death-ligand 1 (PD-1/PD-L1) immune checkpoint –
have brought unprecedented survival benefits in many can-
cers including NSCLC. However, these sustained therapeutic
responses are not seen in all patients; only 20% of patients
with NSCLC currently benefit from these therapies and
immunotherapy may even be deleterious in up to 15% of
patients, who develop a hyper-progressive disease in response
to treatment.3 As such, identifying evidence-based drug
combinations that extend the proportion of patients who
benefit from anti-PD-(L)1 therapy is an active area of study,
as is understanding how to avoid hyper-progression. Recent
discoveries that link the extent of tumor genomic instability
and DNA repair defects to a better outcome on anti-PD-(L)1
therapies have led to the evaluation of anti-PD-(L)1 plus
chemotherapy combination regimens. Such a strategy elicits
impressive efficacy in advanced NSCLC; for example, the
combined use of the anti-PD-1 antibody pembrolizumab
with platinum-based doublet chemotherapy leads to a 12
months overall survival rate of 69.2%,4 an observation that
has led to this combination becoming the new standard first-
line treatment for advanced or metastatic NSCLC. Similarly,
multiple clinical trials that evaluate anti-PD-(L)1 agents in
combination with DNA repair-targeted therapies, such as
PARPi, are being developed.
In many respects, some of these clinical advances have
been made in the absence of strong pre-clinical data that
supports the combined use of DNA repair-targeted therapies
with immunotherapy. In particular, very little is known about
the possible immunomodulatory properties of PARPi, and
pre-clinical data supporting the combination of PARPi with
anti-PD-(L)1 therapies are still scarce. Yet, a growing body of
data has pointed towards a functional interplay between the
DNA damage response (DDR) and anti-cancer immunity.5
The main areas of this interplay include genomic instability/
tumor mutational load and the formation of tumor-specific
neo-antigens, DNA damage-induced immunogenic cell death,
and the activation of cytosolic nucleic acid sensing pathways
in response to DNA insults. In this latter area, several lines of
evidence now support that specific DNA repair defects in
tumor cells can activate, in a cell-autonomous fashion, the
innate immune system via the cyclic GMP-AMP synthase/
stimulator of interferon genes (cGAS/STING) pathway.6,7 In
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normal cells, the cGAS/STING pathway detects foreign cyto-
solic DNA (for example, caused by viral infection) and acti-
vates the innate immune response by stimulating the
expression of a series of pro-inflammatory genes, including
interferon-family genes. But cGAS/STING signaling also
likely plays a tumor suppressive role, by promoting anti-
tumor immunity in response to cytosolic DNA caused by
DNA damage and/or DNA repair defects in cancer cells.
Prior to our work,7 exposing tumor cells to DNA-damaging
agents such as irradiation or S-phase chemotherapies was
known to trigger cGAS/STING signaling,8 but whether DNA
damage caused by PARPi could elicit similar cell-autonomous
immune responses was still unclear. We hypothesized that
PARPi could selectively enhance tumor cell-autonomous
immunity in tumor cells in which they also provoke synthetic
lethality, such as ERCC1-deficient NSCLC cells or BRCA-gene
mutant triple-negative breast cancer (TNBC) cells.
To test this hypothesis, we exploited in-house generated
isogenic NSCLC models of ERCC1 deficiency (ERCC1-WT, -
heterozygous, -knock out (KO) and -rescued clones) and
recently described isogenic series of BRCA1-mutant TNBC
SUM149 cells, that also have additional mutations that either
reverse the homologous recombination defect via reversion of
the pathogenic BRCA1 mutation (BRCA1-revertant cells) or
cause PARPi resistance by mutation of the PARP1 gene itself
(PARP1-null cells).7 Using RNA sequencing and gene set
enrichment analysis in the ERCC1-isogenic NSCLC models,
we found that when compared to ERCC1-WT cells, the tran-
scriptomes of both ERCC1-KO and -heterozygous clones dis-
played an enrichment in the expression of genes related to
immunity, notably genes involved in type I IFN signaling and
cytokine signaling. Interestingly, this transcriptomic analysis –
and further low-throughput validations at the protein level –
also indicated a spontaneous re-expression of STING in
ERCC1-KO clones (which was reversible upon re-expression
of the functional ERCC1 isoform) and a profound upregula-
tion of several chemotactic chemokines, including C-C motif
chemokine ligand 5 (CCL5) and C-X-C motif chemokine
ligand 10 (CXCL10), in cells harbouring a defect in ERCC1.
In addition, using immunohistochemistry on a cohort of stage
I-II resected lung adenocarcinoma, we found that NSCLC
tumors with low ERCC1 expression had increased levels of
tumor-infiltrating lymphocytes (TILs), suggesting that ERCC1
status may influence the nature of the immune infiltrate in
these tumors.
We next sought to evaluate the effects of PARPi on a series
of tumor cell-intrinsic immune phenotypes in ERCC1- or
BRCA1-defective cells. Exposure of NSCLC or TNBC cells to
several clinical PARPi led to a dose-dependent increase in the
formation of cytosolic DNA. The extent of this increase was
dependent upon the status of ERCC1 or BRCA1; indeed,
whilst cytosolic DNA induction was limited in ERCC1-WT
and BRCA1-revertant cells, we observed a much more sub-
stantial accumulation of cytosolic DNA in ERCC1-deficient
and BRCA1-mutated cells, which displayed elevated levels of
cytoplasmic chromatin fragments and micronuclei. Further,
we found that cGAS, the critical DNA-binding factor of the
cGAS/STING signaling cascade, localized to these micronu-
clei. We also noted that this increase in cytosolic DNA was
associated with activation of STING signaling – as evidenced
by the phosphorylation of TANK-binding kinase 1 (TBK1),
interferon regulatory factors 3 and 7 (IFR3, IRF7), and
nuclear factor-kappa B (NF-κB) –, a resultant type I IFN
response and the release chemotactic chemokines, including
CCL5 (Figure 1). Importantly, these effects were suppressed in
ERCC1-rescued NSCLC cells and BRCA1-revertant TNBC
cells, suggesting that extant DNA repair defects are required
to induce profound cell-autonomous innate immune-related
phenotypes in response to PARPi. We also used PARP1-null
cells to assess whether these PARPi-induced effects were on-
target effects caused by PARP1 inhibition, as opposed to the
inhibition of other PARP-superfamily members; we found
that genetic ablation of PARP1 completely reversed the acti-
vation of cGAS/STING signaling, supporting an on-target
effect of PARPi.
Taken together, these experiments uncovered a novel and
relatively unexpected role of PARPi, that is to modulate anti-
tumor immunity through a tumor cell-intrinsic mechanism.
Importantly, our study identified the genomic contexts (i.e.,
loss of ERCC1 or BRCA1 function) in which these immuno-
modulatory effects operate, thereby providing meaningful
data for appropriately selecting patients in the clinic. Our
findings are consistent with other recent publications;9,10
notably and very interestingly, Ding and colleagues reported
that PARPi elicit potent anti-tumor immunity in BRCA1-
deficient ovarian tumors following activation of STING sig-
naling, not only in tumor cells but also in dendritic cells –
thereby suggesting a link between innate immunity and sys-
temic adaptive immune responses. In Ding et al.’s model, the
addition of anti-PD-1 therapy enhanced the BRCA1-
dependent and CD8+ T cell-dependent anti-
tumor efficacy of PARPi – a finding that was also previously
reported by Robillard et al..11
To conclude, our work,7 which uses a combination of
rigorous and well-characterized isogenic systems, provides
a scientific rationale for combining PARPi with anti-PD-(L)
1 therapy in molecularly selected DNA repair-deficient popu-
lations. While several clinical trials are currently assessing this
combination in BRCA1/2-mutant breast or ovarian cancers,
other cancer types, such as NSCLC in which ERCC1 is fre-
quently defective and anti-PD-(L)1 therapies have already
shown impressive results, may also benefit from this thera-
peutic strategy. Such evaluation is underway.
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Figure 1. Proposed model of PARPi-induced cancer cell-autonomous immunity in DNA repair-deficient cancer cells.
A. DNA repair-proficient cells, such as wildtype excision repair cross-complementation group 1 (ERCC1) and breast cancer type 1 susceptibility gene (BRCA1) cells,
adequately repair endogenous DNA lesions. B. Poly-(ADP-ribose) polymerase inhibitors (PARPi) exposure causes DNA damage, mostly initiated by PARP1 itself
trapped onto the DNA at sites of spontaneous single-strand breaks (SSBs). Trapped-PARP1 generates stalled replication forks and subsequent double-strand breaks
(DSBs) during DNA replication. C. In DNA repair-proficient cells, trapped-PARP1 lesions can be adequately excised, a process which is likely to be orchestrated by
ERCC1. Following excision, BRCA1-mediated repair of DSBs occurs through homologous recombination, and replication restarts. D. Residual unrepaired lesions cause
a minimal formation of cytoplasmic chromatin fragments, which are insufficient to trigger cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS/STING)
signaling cascade. By contrast, DNA repair-deficient cells, such as ERCC1-deficient and BRCA1-mutated cells are exposed to increase levels of endogenous DNA
damage (E, F), which are further enhanced upon exposure to PARPi (G, H). I. In ERCC1-deficient cells, trapped-PARP1 lesions cannot be appropriately resolved, which
prevents the subsequent processing of DSBs through homologous recombination. J. In BRCA1-mutated cells, several steps of homologous recombination are disabled
and DSB repair cannot occur. K, L. In either case, this results in the accumulation of stalled replication forks, subsequent DSBs and unrepaired DNA lesions which
eventually causes increased micronuclei formation and cytoplasmic chromatin fragments generation. These are detected by cGAS, which activates the cGAS/STING
signaling cascade and results in a type I IFN response characterized by the secretion of C-C motif chemokine ligand 5 (CCL5) and other chemotactic cytokines.
Abbreviations: pTBK1, phosphorylated TANK-binding kinase 1; pIRF3, phosphorylated interferon regulatory factor 3; pNF-κB, phosphorylated nuclear factor-kappa B.
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